SCHEMBL9625918

SCHEMBL9625918

C[N+](C)(C)CC(CC(=O)[O-])OC(=O)Cc1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.60
KMT2A Q03164 4/20 0.60
CYP2C19 P33261 2/20 0.60
RECQL P46063 1/20 0.60
CYP1A2 P05177 3/20 0.55
HRH1 P35367 1/20 0.55
TSHR P16473 3/20 0.53
SLC25A20 O43772 3/20 0.52
TP53 P04637 2/20 0.52
CYP2D6 P10635 2/20 0.52
SLC6A5 Q9Y345 2/20 0.52
MAPT P10636 2/20 0.52
KDM4E B2RXH2 1/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2C9 P11712 1/20 0.52
NFKB1 P19838 1/20 0.52
THPO P40225 1/20 0.52
HIF1A Q16665 1/20 0.52
HSD17B10 Q99714 1/20 0.52
CPT2 P23786 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20985204 0.89 TSHR (0.55) MEN1KMT2ACYP2C19RECQLCYP1A2
SCHEMBL25287108 0.88 MEN1 (0.58) MEN1KMT2ACYP2C19RECQLCYP1A2
Propionyl-Carnitine SCHEMBL5935669 0.80 MEN1 (0.72) MEN1KMT2ACYP2C19RECQLCYP1A2
Levocarnitine Propionate SCHEMBL5935670 0.80 MEN1 (0.72) MEN1KMT2ACYP2C19RECQLCYP1A2
SCHEMBL2201976 0.80 MEN1 (0.50) MEN1KMT2ACYP2C19RECQLCYP1A2
SCHEMBL9634318 0.80 MEN1 (0.50) MEN1KMT2ACYP2C19RECQLCYP1A2
SCHEMBL5935732 0.80 MEN1 (0.58) MEN1KMT2ACYP2C19RECQLCYP1A2
SCHEMBL5935734 0.80 MEN1 (0.58) MEN1KMT2ACYP2C19RECQLCYP1A2
SCHEMBL11064402 0.80 MEN1 (0.55) MEN1KMT2ACYP2C19RECQLCYP1A2
SCHEMBL31742464 0.80 MEN1 (0.55) MEN1KMT2ACYP2C19RECQLCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4537111-A2 MULTI-OMICS ASSESSMENT Prognomiq Inc (US) 2025-04-16 EP claimed
CN-119816897-A Multiple study assessment 普罗科技有限公司 2025-04-11 CN claimed
WO-2023240046-A2 MULTI-OMICS ASSESSMENT PrognomIQ, Inc. (US) 2023-12-14 WO claimed
US-20260034086-A1 Pet Food Compositions Comprising Caprylic Acid And Docosahexaenoic Acid And/Or Eicosapetaenoic Acid For Use In Treating Struvite Urolithiasis HILL'S PET NUTRITION, INC. (US) 2026-02-05 US disclosed
US-20250388973-A1 MULTI-OMICS ASSESSMENT PROGNOMIQ INC (US) 2025-12-25 US disclosed
US-20250375505-A1 COMPOSITIONS AND METHODS FOR MODIFYING BILE ACIDS TO REGULATE LIPID AND STEROID METABOLISM UNIV CALIFORNIA (US) 2025-12-11 US disclosed
US-12458617-B2 Pet food compositions comprising caprylic acid and docosahexaenoic acid and/or eicosapetaenoic acid for use in treating struvite urolithiasis HILL'S PET NUTRITION, INC. (US) 2025-11-04 US disclosed
EP-3709817-B2 COMPOSITIONS COMPRISING OMEGA-3 POLYUNSATURATED AND MEDIUM CHAIN FATTY ACIDS HILLS PET NUTRITION INC (US) 2025-10-22 EP disclosed
EP-4537111-A2 MULTI-OMICS ASSESSMENT Prognomiq Inc (US) 2025-04-16 EP disclosed
CN-119816897-A Multiple study assessment 普罗科技有限公司 2025-04-11 CN disclosed
US-20240257973-A1 DISEASE SPECTRUM CLASSIFICATION PATIENTSLIKEME LLC (US) 2024-08-01 US disclosed
US-9176113-B1 Methods and systems for determining autism spectrum disorder risk SYNAPDX CORPORATION (US) 2015-11-03 US disclosed
US-20150293072-A1 METHODS AND SYSTEMS FOR DETERMINING AUTISM SPECTRUM DISORDER RISK LABORATORY CORPORATION OF AMERICA HOLDINGS 2015-10-15 US disclosed
WO-2015157601-A1 METHODS AND SYSTEMS FOR DETERMINING AUTISM SPECTRUM DISORDER RISK SYNAPDX CORPORATION (US) 2015-10-15 WO disclosed
US-20150294081-A1 METHODS AND SYSTEMS FOR DETERMINING AUTISM SPECTRUM DISORDER RISK LABORATORY CORPORATION OF AMERICA HOLDINGS 2015-10-15 US disclosed
EP-0215697-B1 ACYLCARNITINES AS ABSORPTION-ENHANCING AGENTS FOR DRUG DELIVERY THROUGH MUCOUS MEMBRANES OF THE NASAL, BUCCAL, SUBLINGUAL AND VAGINAL COMPARTMENTS MERCK & CO. INC. (US) 1992-03-25 EP disclosed
US-4963525-A POLYPEPTIDES MERCK & CO., INC. (US) 1990-10-16 US disclosed
US-4847298-A DOPA COMPOUNDS OR ANTIBIOTICS MERCK & CO., INC. (US) 1989-07-11 US disclosed
US-4731360-A Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments MERCK & CO., INC. (US) 1988-03-15 US disclosed
EP-0215697-A2 Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments MERCK & CO. INC. (US) 1987-03-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250375505-A1 COMPOSITIONS AND METHODS FOR MODIFYING BILE ACIDS TO REGULATE LIPID AND STEROID METABOLISM CYP27A1, LIPC, CYP46A1 MEN1 2550/4885KMT2A 3068/4885CYP2C19 1364/4885
US-20250388973-A1 MULTI-OMICS ASSESSMENT S100A4, APOL1, SAAL1 MEN1 3308/4885KMT2A 4778/4885CYP2C19 3099/4885
US-20260034086-A1 Pet Food Compositions Comprising Caprylic Acid And Docosahexaenoic Acid And/Or Eicosapetaenoic Acid For Use In Treating Struvite Urolithiasis FPR2, FPR1, FPR3 MEN1 3045/4885KMT2A 4550/4885CYP2C19 2315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.